Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 1interventionalRules rewrite

Phase 1: testing Bicalutamide 50 mg for NAFLD

Nonalcoholic steatohepatitis (NASH), or fat-related liver inflammation and scarring is projected to be the leading cause of cirrhosis in the United States (U.S.) within the next few years. Women are at disproportionate risk for NASH, with approximately 15 million U.S.

Official registry: https://clinicaltrials.gov/study/NCT05979389 · University of California, San Francisco · enrollment listed as 50

What this phase means

Phase 1: the first tests in people. The main question is safety and dose, not whether it cures the condition. Groups are small. Side effects are watched closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Bicalutamide 50 mg, or Placebo. The registry lists allocation as randomized. Nonalcoholic steatohepatitis (NASH), or fat-related liver inflammation and scarring is projected to be the leading cause of cirrhosis in the United States (U.S.) within the next few years.

They plan to enroll about 50 people at San Francisco. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Pilot Trial of Bicalutamide Versus Placebo in Reproductive-Aged Women With Nonalcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovary Syndrome (PCOS)

Interventions: Bicalutamide 50 mg, Placebo

Primary outcome (registry wording): Change in liver stiffness on Magnetic Resonance Elastography (MRE)

Who it is for (from inclusion criteria)

  • Ages 18 Years to 42 Years
  • Women only
  • Women aged 18-42 years with hyperandrogenic PCOS
  • NASH identified on liver biopsy or probable NASH on transient elastography- controlled attenuation parameter (TE-CAP) with cutoffs defined as CAP score ≥270 decibel/m and TE score \> 7.0 kPA or alanine aminotransferase ≥40 U/L)

Public study contact (from the registry)

Lily Carbullido

(415)-502-3725

myliverhealth@ucsf.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseMontreal, Quebec
Not a traditional drug phase: Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE) for Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).

NCT03572465 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)

RecruitingNot a traditional drug phaseNew Haven, Connecticut
Not a traditional drug phase: testing Vitamin D 4000IU daily for Polycystic Ovarian Syndrome in Adolescent Females

This study is a double blind, dummy treatment (placebo) controlled, randomly assigned trial of study subjects with PCOS and low vitamin D to 2 groups- dummy treatment (placebo) and vitamin D replacement. Participants and investigators will be blinded to treatment modality until the end of the trial period

NCT04355572 · Official ClinicalTrials.gov record · Yale University

RecruitingPhase 3Aurora, Colorado
Phase 3: testing Semaglutide Injectable Product (Wegovy and/or Ozempic) for PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.

NCT05819853 · Official ClinicalTrials.gov record · University of Colorado, Denver

FAQ about this NCT record

Is NCT05979389 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT05979389?

Phase 1. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT05979389?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary